PCRX - Pacira BioSciences sees 32% growth in Q1 revenue: Prelim

Pacira BioSciences (NASDAQ:PCRX) on Tuesday has announced preliminary revenue estimate of $157.4-$158.4M for Q1 2022, up from $119M revenue reported last year. It includes: EXPAREL product sales, $129.2M; ZILRETTA product revenue following Flexion Therapeutics acquisition, $23-$24M; and iovera° revenue, $3-$3.3M. Royal revenue for the quarter was $0.6M. EXPAREL's March sales stood at $51.2M (vs. $44.3M in 1Q21). "The increase was driven by the continued expansion and institutionalization of EXPAREL-based blocks as the foundation of enhanced recovery protocols across a variety of surgical procedures," said CEO Dave Stack. Earlier: Pacira Biosciences reports February preliminary net product sales for EXPAREL and iovera of $42.6M

For further details see:

Pacira BioSciences sees 32% growth in Q1 revenue: Prelim